[1] Parodi A J. Reglucosylation of glycoproteins and quality control of glycoprotein folding in the endoplasmic reticulum of yeast cells[J]. Biochim Biophys Acta, 1999,1426(2):287-295.[2] Arnold J N, Wormald M R, Sim R B, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins[J]. Annu Rev Immunol, 2007,25:21-50.[3] Litynska A, Przybylo M, Pochec E, et al. Comparison of the lectin-binding pattern in different human melanoma cell lines[J]. Melanoma Res, 2001,11(3):205-212.[4] Krishnan V, Bane S M, Kawle P D, et al.Altered melanoma cell surface glycosylation mediates organ specific adhesion and metastasis via lectin receptors on the lung vascular endothelium[J]. Clin Exp Metastasis, 2005,22(1):11-24.[5] Ding N, Nie H, Sun X, et al. Human serum N-glycan profiles are age and sex dependent[J]. Age Ageing, 2011,40(5):568-575.[6] Knezevic A, Gornik O, Polasek O, et al. Effects of aging, body mass index, plasma lipid profiles, smoking on human plasma N-glycans[J]. Glycobiology, 2010,20(8):959-969.[7] Ahn J M, Sung H J, Yoon Y H, et al. Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer[J]. Mol Cell Proteomics, 2014,13(1):30-48.[8] Ruhaak L R, Nguyen U T, Stroble C, et al. Enrichment strategies in glycomics-based lung cancer biomarker development[J]. Proteomics Clin Appl, 2013,11(3):1-20.[9] Zhao Y P, Ruan C P, Wang H, et al. Identification and assessment of new biomarkers for colorectal cancer with serum N-glycan profiling[J]. Cancer, 2012,118(3):639-650.[10] Saeland E, Belo A I, Mongera S, et al. Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients[J]. Int J Cancer, 2012,131(1):117-128.[11] Saldova R, Reuben J M, Abd Hamid U M, et al. Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts[J]. Ann Oncol, 2011,22(5):1113-1119.[12] Saldova R, Fan Y, Fitzpatrick J M, et al. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia[J]. Glycobiology, 2011,21(2):195-205.[13] 何椿鹏,华玲,杨小盼,等.不同肿瘤坏死因子受体-Fc融合蛋白N-糖基化修饰糖链的初步分析[J].国际药学研究杂志,2013,3:344-349,364.[14] 徐秀英.低糖基化E-钙粘蛋白对舌癌细胞增殖、侵袭和迁移的影响[D].济南:山东大学,2012.[15] 姚媛菲.乳腺癌细胞系N-糖基化特征性糖链的分析[D].哈尔滨:哈尔滨工业大学,2009.[16] 丁宁.乳腺癌患者与健康人血清N-糖基化糖链差异的比较分析[D].哈尔滨:哈尔滨工业大学,2009.[17] Knezevic A, Polasek O, Gornik O, et al. Variability, heritability and environmental determinants of human plasma N-glycome[J]. J Proteome Res, 2009,8(2):694-701.[18] Byerley L O, Leamy L, Tam S W, et al. Development of a serum profile for healthy aging[J]. Age: Dordr, 2010,32(4):497-507.[19] Vanhooren V, Laroy W, Libert C, et al. N-glycan profiling in the study of human aging[J]. Biogerontology, 2008,9(5):351-356.[20] Vanhooren V, Liu X E, Franceschi C, et al. N-glycan profiles as tools in diagnosis of hepatocellular carcinoma and prediction of healthy human ageing[J]. Mech Ageing Dev, 2009,130(1-2):92-97.[21] Lu J P, Knezevic A, Wang Y X, et al. Screening novel biomarkers for metabolic syndrome by profiling human plasma N-glycans in Chinese Han and Croatian populations[J]. J Proteome Res, 2011,10(11):4959-4969. |